


**To:** [redacted] 5.1.2e @ec.europa.eu [redacted] 5.1.2e  
[redacted] 5.1.2e @ec.europa.eu]  
**Cc:** [redacted] 5.1.2e [redacted] 5.1.2e @ec.europa.eu]; [redacted] 5.1.2e, [redacted] 1.2. (5.1.2e) [redacted] 5.1.2e @minvws.nl]; [redacted] 5.1.2e, [redacted] 5.1.2e, [redacted] 5.1.2e ) [redacted] 5.1.2e @minvws.nl]  
**From:** [redacted] 5.1.2e [redacted] 5.1.2e  
**Sent:** Wed 3/3/2021 8:44:20 PM  
**Subject:** RE: SENSITIVE - important information on joint procurement of monoclonal antibodies  
**Received:** Wed 3/3/2021 8:44:22 PM

Dear JP Team,

We would like to inform you that the Netherlands is interested in the product VIR-7831 from GSK and would like to participate in the JP.  
However, we have not completed our needs assessment for this product yet, but will inform you as soon as possible.

Best regards,

[redacted] 5.1.2e



Dubbel

Dubbel